COMMUNIQUÉS West-GlobeNewswire

Route 92 Medical Announces First Commercial Cases in Canada
22/06/2026
Procedures follow Health Canada Medical Device License for the Company’s advanced neurovascular portfolio More than 100,000 patients suffer from strokes annually in Canada WEST JORDAN, Utah, June 22, 2026 (GLOBE [...]
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
22/06/2026
Allowed claims directly support the Company’s ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers HOUSTON, June 22, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“ [...]
SeaStar Medical to Present at Upcoming Investor Summit Conference
22/06/2026
DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure [...]
Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis
22/06/2026
Enrollment expected to complete Q1 2027; topline results anticipated 1H 2028; BLA filing targeted for 2H 2028 Phase 1/2 data demonstrated ATSN-201's ability to reverse structural damage to the retina and improve vision [...]
Novo Nordisk A/S - share repurchase programme
22/06/2026
Bagsværd, Denmark, 22 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
22/06/2026
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million [...]
Weight Watchers to Support the American Heart Association’s Healthy Living BEYOND Weight Study
22/06/2026
Weight Watchers helps members achieve lasting weight loss through medication, personalized nutrition, and community support. As part of its collaboration with the American Heart Association, Weight Watchers is [...]
TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic Stroke
22/06/2026
FAIR HAVEN, N.J. and ITHACA, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- TETmedical, Inc., a clinical stage medical diagnostics company developing rapid tools for diagnosing acute neurological injury based on its patented [...]
GuideAI Health Receives FDA 510(k) Clearance for VascularAssist Occlusion Triage
22/06/2026
AI-Powered Triage Software Helps Radiologists Identify and Prioritize Peripheral Vascular Disease in Lower-Extremity CT Imaging BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (" GuideAI " or the " [...]
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
22/06/2026
EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today [...]
NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization
22/06/2026
Strong Capitalization Foundation Supports Strategic Growth and Market Stability BANGKOK, June 22, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”) today announced that NewGen’s [...]
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
22/06/2026
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which [...]
Catheter Precision, Inc. Announces Allowance of Key Intellectual Property
22/06/2026
Eight New Patents Issued on Heart Failure Technology Three New Patents Granted on Vascular Closure Technology FORT MILL, S.C., June 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK: NYSE/American), today [...]
CurePSP Expands Grant Program with $155,000 Investment in Studying Care for Rare Neurological Diseases
22/06/2026
NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- CurePSP announced the latest recipients of the Collaborative Approaches to Resources, Education and Support (CARES) grants, awarding a total of $155,000 to four projects [...]
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
22/06/2026
PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for [...]
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
22/06/2026
Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
22/06/2026
The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizures (p=0.015), with [...]
Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors
22/06/2026
– Series B proceeds will fund clinical proof-of-biology studies of SARM1 inhibitors – First patient dosed in Phase 1b/2a ALS study with NB-4746, an oral, brain-penetrant SARM1 inhibitor – Dosing initiated in a first-in- [...]
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
22/06/2026
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026 [...]

Pages